HIV Research Highlights From First Day of CROI 2018
March 6, 2018
Advances in HIV research are being shared this week at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, and HIV.gov is here sharing news and information about some of the important new findings and data being released. We conducted a Facebook Live interview with Dr. Carl Dieffenbach on Monday afternoon to learn about some of the key research findings presented during the first full day of sessions. Dr. Dieffenbach is the Director of the Division of AIDS at NIH's National Institute of Allergy and Infectious Diseases (NIAID) and he spoke with his colleague Anne Rancourt.
If you have trouble viewing the embedded Facebook live video, you can view it on Facebook.
Finally, Dr. Dieffenbach also highlighted another NIH-supported study that may hold promise to inform ongoing efforts to find a cure for HIV. The study of broadly neutralizing antibody treatment found that this antibody, paired with another drug, had a profound impact on time to viral rebound and possibly the viral reservoir in monkeys infected with an HIV-like virus. Read the NIAID news release about this study.
[Note from TheBodyPRO: This article was originally published by HIV.gov on March 6, 2018. We have cross-posted it with their permission.]
No HIV Evolution in Plasma or Lymph Nodes on Suppressive ART and No Impact From Further Intensification
This article was provided by HIV.gov. It is a part of the publication The 25th Conference on Retroviruses and Opportunistic Infections.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.